Aetram Research India: NIFTY PHARMA Weekly Sector Outlook
Nifty Pharma maintains a positive structure; strength above 27,050 may extend momentum, while weakness below 26,600 can trigger a deeper consolidation phase - 26.09.2026
Current Market Price: 26996.25
Market Prediction:
- Nifty Pharma continues to hold a relatively stronger structure compared with broader sectors, trading above major average support zones. RSI remains near neutral-positive territory, indicating stable momentum, while MACD shows short-term weakness within a broader positive trend. Sustaining the 26,700 zone remains important, with further strength possible after clearing immediate resistance levels.
Upcoming Events:
- US healthcare trends and global pharma demand outlook may influence sector sentiment.
- Regulatory updates and drug approval developments remain important sector catalysts.
- Currency movement and export-related factors may impact pharmaceutical companies.
Major Support and Resistance:
- Support: 26700, 26550, 26350
- Resistance: 27050, 27250, 27500
Volume Analysis:
- Volume participation remains balanced with selective buying interest near support zones. Recent activity indicates accumulation at lower levels, but stronger volume expansion near resistance areas is required to confirm continuation of positive momentum.
Final Take Away:
- Nifty Pharma continues to demonstrate relative strength with a stable price structure near higher levels. Holding above 26,700 keeps recovery momentum intact, while sustained movement above 27,050 can improve the possibility of further upside continuation.
Next Week Prediction:
- Nifty Pharma may maintain a positive-to-consolidation phase. Strength above resistance can support higher levels, while weakness below support may invite profit booking.
Scenario-Based Outlook:
- Bullish Scenario: Above 27050, price may move toward 27250–27500 zone.
- Bearish Scenario: Below 26600, downside risk toward 26350–26150 zone.
- Neutral Scenario: Between 26600–27050, consolidation likely.
Disclaimer: This research report is for informational purposes only. This is not an offer to buy or sell securities. Past performance is not indicative of future results. There is no guarantee of returns. Investments in securities are subject to market risks including loss of capital. Investors should consult their financial advisor before making any investment decisions.
